# Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma

> **NCT01248975** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 145 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** FP/SAL 250/50mcg BID
- **DRUG:** GSK2190915 200mg QD (AM)
- **DRUG:** GSK2190915 100mg QD (AM)
- **DRUG:** Montelukast 10mg QD (PM)
- **DRUG:** Placebo tablets (2) (AM)
- **DRUG:** Placebo capsule (PM)

## Key facts

- **NCT ID:** NCT01248975
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2016-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01248975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01248975, "Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01248975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*